20:16 , Mar 24, 2017 |  BC Week In Review  |  Company News

Critical Path biomarker consortium

The Critical Path Institute launched a consortium that will aim to qualify biomarkers for Type I diabetes with FDA and EMA. The Leona M. and Harry B. Helmsley Charitable Trust, the Janssen Research & Development...
21:59 , Mar 21, 2017 |  BC Extra  |  Politics & Policy

C-PATH consortium seeks to qualify diabetes biomarkers

The Critical Path Institute (Tucson, Ariz.) launched a consortium that will aim to qualify biomarkers for Type I diabetes with FDA and EMA. The Leona M. and Harry B. Helmsley Charitable Trust, the Janssen Research &...
23:52 , Feb 24, 2017 |  BC Extra  |  Clinical News

A T-cell gene signature in infants could predict Type I diabetes

German researchers published a gene signature found in T cells from six month old infants that preceded the development of β cell autoantibodies in those at high risk for Type I diabetes. The paper was...
07:00 , Oct 6, 2014 |  BioCentury  |  Emerging Company Profile

Nirmidas: Improving NIR-sightedness

Nirmidas Biotech Inc.'s pGOLD platform can amplify the signal output of near-infrared fluorescent dyes over a hundredfold, which improves their sensitivity for low-concentration analytes in ELISA or other assays that rely on fluorescent readouts. The...
07:00 , Oct 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Histone deacetylase (HDAC); glutamate decarboxylase 2 (GAD2; GAD65) Rodent studies suggest inhibiting HDACs could help treat...
01:18 , Jun 24, 2011 |  BC Extra  |  Clinical News

Diamyd falls after second Phase III miss

Diamyd Medical AB (SSE:DIAM B) fell SEK1.60 (15%) to SEK9 on Thursday after the company said it will discontinue the U.S. Phase III DiaPrevent trial of subcutaneous Diamyd to treat newly diagnosed Type I diabetics....
07:00 , Jun 6, 2011 |  BC Week In Review  |  Company News

Diamyd, J&J deal

Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary terminated a 2010 deal with Diamyd and returned rights to diabetes candidate Diamyd. In May, the product missed the primary endpoint in a European Phase III trial to...
00:08 , Jun 2, 2011 |  BC Extra  |  Top Story

J&J returns Diamyd rights

Johnson & Johnson (NYSE:JNJ) subsidiary Ortho-McNeil-Janssen Pharmaceuticals Inc. terminated a 2010 deal with Diamyd Medical AB (SSE:DIAM B) and returned rights to diabetes candidate Diamyd. The news sent shares of Diamyd falling SEK1.40 (12%) to...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Company News

Diamyd Medical, J&J deal

Diamyd granted Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. unit exclusive rights to Diamyd diabetes vaccine outside Nordic countries. The recombinant human glutamic acid decarboxylase (GAD65) subcutaneous vaccine is in two Phase III trials to...
07:00 , Jun 28, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Regulatory milestones Celgene Corp. (NASDAQ:CELG) gained $0.72 to $56.07 last week after Japan's Ministry of Health, Labor and Welfare (MHLW) approved Revlimid lenalidomide in combination with dexamethasone to treat relapsed or refractory multiple myeloma (MM). Genmab A/S...